Diagnosis & Treatment Blogs

Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are

Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming

Read time: 2 minutes. Many people have heard of HER2-positive breast cancer. But HER2 is an important biomarker found in many different types of cancer—including non-small cell

Read time: 3 minutes. Editors Note: If you missed the 2024 International Lung Cancer Survivorship Conference (ILCSC), make sure to join our email list and be the first to know when

Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with

Read time: 1 minute On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK

Read time: 2 minutes The question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer

On May 16, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive stage small cell lung

Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these

Read time: 4 minutes Lung cancer screening guidelines were first issued by the United States Preventive Services Task Force in 2013 to help doctors find lung cancer in its earliest

Lung cancer experts from Johns Hopkins Kimmel Cancer Center dive into the how and why behind targeted therapy, immunotherapy, and radiation therapy. Touching on improvements to

LUNGevity blogs share personal stories, research updates, scientific meeting takeaways, policy news, and much more. Joining our Email List will help you stay updated on these